Grifols SA (GRFS) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, Grifols SA's filing signal continuing positive.

Grifols, S.A. is a global biopharmaceutical company specializing in plasma-derived medicines and in vitro diagnostics, ranking among the top three producers worldwide by sales. With over 70 years of experience, the company operates a vertically integrated model, encompassing plasma collection, manufacturing, and distribution. Grifols maintains a vast network of over 400 plasma collection centers across the United States, Europe, Canada, and Egypt. Its Biopharma segment, accounting for 86.2% of 2025 revenue, focuses on therapeutic proteins like immunoglobulins, Alpha-1 antitrypsin, and albumin. The Diagnostic segment, contributing 8.5% of revenue, offers in vitro diagnostic products for clinical and blood bank laboratories. The company's products are sold in over 100 countries, with a direct presence in more than 30.

Revenue is primarily driven by the Biopharma segment, particularly sales of immunoglobulin products, followed by Diagnostic products and Bio Supplies. Geographic revenue is significantly influenced by the United States and Canada, which accounted for 56.5% of total net revenue in 2025.